ES2139227T3 - Concentrado de fibrinogeno obtenido de plasma sanguineo, procedimiento e instalacion para su preparacion. - Google Patents

Concentrado de fibrinogeno obtenido de plasma sanguineo, procedimiento e instalacion para su preparacion.

Info

Publication number
ES2139227T3
ES2139227T3 ES95927599T ES95927599T ES2139227T3 ES 2139227 T3 ES2139227 T3 ES 2139227T3 ES 95927599 T ES95927599 T ES 95927599T ES 95927599 T ES95927599 T ES 95927599T ES 2139227 T3 ES2139227 T3 ES 2139227T3
Authority
ES
Spain
Prior art keywords
procedure
installation
preparation
blood plasma
fibrinogen concentrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95927599T
Other languages
English (en)
Other versions
ES2139227T5 (es
Inventor
Ruth Laub
Wael Luc De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CAF DCF DEPARTEMENT CENTRAL DE
Original Assignee
CAF DCF DEPARTEMENT CENTRAL DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8218658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139227(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CAF DCF DEPARTEMENT CENTRAL DE filed Critical CAF DCF DEPARTEMENT CENTRAL DE
Publication of ES2139227T3 publication Critical patent/ES2139227T3/es
Application granted granted Critical
Publication of ES2139227T5 publication Critical patent/ES2139227T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0042—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN CONCENTRADO DE FIBRINOGENO CARACTERIZADO PORQUE ESTA DESPROVISTO DE CONTAMINANTES VIRALES Y PORQUE SU PUREZA ES SUPERIOR A 95%. LA PRESENTE INVENCION SE REFIERE TAMBIEN AL PROCEDIMIENTO DE OBTENCION DE DICHO CONCENTRADO DE FIBRINOGENO.
ES95927599T 1994-07-14 1995-07-14 Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación. Expired - Lifetime ES2139227T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94870121 1994-07-14
EP94870121 1994-07-14

Publications (2)

Publication Number Publication Date
ES2139227T3 true ES2139227T3 (es) 2000-02-01
ES2139227T5 ES2139227T5 (es) 2011-05-04

Family

ID=8218658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95927599T Expired - Lifetime ES2139227T5 (es) 1994-07-14 1995-07-14 Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación.

Country Status (9)

Country Link
US (1) US5834420A (es)
EP (1) EP0771324B2 (es)
JP (1) JP4211894B2 (es)
AT (1) ATE184884T1 (es)
CA (1) CA2195127C (es)
DE (1) DE69512416T3 (es)
ES (1) ES2139227T5 (es)
IL (1) IL122665A (es)
WO (1) WO1996002571A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184884T1 (de) * 1994-07-14 1999-10-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
EP0840624B1 (fr) * 1995-07-14 2007-07-25 CAF - DCF cvba - scrl Installation d'inactivation de contaminants viraux presents dans des produits sanguins
EP1115742B1 (en) * 1998-09-24 2006-03-29 Pharming Intellectual Property BV Purification of fibrinogen from milk by use of cation exchange chromatography
DK1115745T3 (da) 1998-09-24 2006-10-02 Pharming Intellectual Pty Bv Oprensning af fibrinogen fra væsker ved udfældning og hydrofob interaktionskromatografi
FR2785206B1 (fr) * 1998-10-14 2001-01-19 Fond Jean Dausset Ceph Dispositif de centrifugation pour automate de laboratoire
US6946140B1 (en) * 1999-02-09 2005-09-20 The Research Foundation Of State University Of New York Methods and compositions for enhancing fibroblast migration
CN1192781C (zh) * 1999-12-20 2005-03-16 三菱制药株式会社 用多孔膜处理的无病毒血浆蛋白组合物及其生产方法
NZ518692A (en) * 1999-12-23 2004-08-27 Csl Ltd Purified fibrinogen free of destabilising levels of plasminogen and other proteases obtained from a Fraction I paste
US20030086817A1 (en) * 2001-11-06 2003-05-08 Horton Isaac B. Blood purification system
WO2003070285A1 (en) * 2002-02-19 2003-08-28 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
AU2004216476B2 (en) 2003-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Method for the validatable inactivation of pathogens in a biological fluid by irradiation
US20050124038A1 (en) * 2003-07-14 2005-06-09 Pharmacia Corporation Transfection of cartilage and matrices thereof in vitro
ES2396689T3 (es) 2003-12-11 2013-02-25 Isto Technologies Inc. Sistema de cartílago particulado
EP1753860B1 (en) * 2004-02-20 2012-04-11 Isto Technologies Inc. Intervertebral disc repair and methods therefor
DE102004009400A1 (de) * 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
RU2411959C2 (ru) * 2004-06-29 2011-02-20 Релайанс Лайф Сайенсиз Пвт Лтд Способ получения безопасных в вирусном отношении биологических текучих сред
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
CA2714281A1 (en) * 2008-03-28 2009-10-01 Research Foundation For Medical Devices Method of viral inactivation of biological fluids by solvent/detergent-treatment
RU2603103C2 (ru) * 2010-09-20 2016-11-20 Октафарма Аг Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт
US20140287044A1 (en) * 2011-03-04 2014-09-25 Rare Antibody Antigen Supply, Inc. Fibrin sealant (fibringluraas) consisting of a kit of lyophilized or frozen high concentrate fribinogen
MX351340B (es) * 2012-03-13 2017-10-11 Octapharma Ag Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este.
CH706420A1 (fr) * 2012-04-19 2013-10-31 Valerie Soulie Procédé d'inactivation virale d'un fluide biologique, dispositif et récipient pour la mise en œuvre d'un tel procédé.
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
IL231230A0 (en) 2014-02-27 2014-08-31 Omrix Biopharmaceuticals Ltd Fibrinogen preparation
US9932388B2 (en) 2014-11-13 2018-04-03 Hemarus Therapeutics Limited Chromatographic process for producing high purity fibrinogen and thrombin
US20230022328A1 (en) * 2019-12-10 2023-01-26 Biotest Ag Method for Manufacturing a Fibrinogen Preparation
CN111518197B (zh) * 2020-03-30 2024-01-05 哈尔滨派斯菲科生物制药有限公司 一种纤维蛋白原的生产方法
JP7645133B2 (ja) * 2021-06-04 2025-03-13 Ｋｍバイオロジクス株式会社 血液凝固第ｘｉｉｉ因子を含むフィブリノゲンの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598196A (en) † 1979-01-16 1980-07-25 Meito Sangyo Kk Fractionation of fibrinogen or its constituents and their use
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4481189A (en) † 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GB8505882D0 (en) * 1985-03-07 1985-04-11 Central Blood Lab Authority Purification of blood coagulation factor viii
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
ES2057191T5 (es) † 1989-01-13 2003-05-01 Mitsubishi Pharma Corp Metodo de produccion para una composicion que contiene proteinas.
EP0602173B1 (en) * 1991-09-05 1999-05-26 Baxter International Inc. Topical fibrinogen complex
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
ATE184884T1 (de) * 1994-07-14 1999-10-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung

Also Published As

Publication number Publication date
EP0771324B1 (fr) 1999-09-22
CA2195127A1 (en) 1996-02-01
CA2195127C (en) 2007-06-19
JP4211894B2 (ja) 2009-01-21
JPH10506607A (ja) 1998-06-30
DE69512416T2 (de) 2000-02-17
DE69512416D1 (de) 1999-10-28
IL122665A0 (en) 1998-08-16
WO1996002571A1 (fr) 1996-02-01
EP0771324B2 (fr) 2011-02-09
DE69512416T3 (de) 2011-12-15
US5834420A (en) 1998-11-10
EP0771324A1 (fr) 1997-05-07
ATE184884T1 (de) 1999-10-15
IL122665A (en) 2001-08-26
ES2139227T5 (es) 2011-05-04

Similar Documents

Publication Publication Date Title
ES2139227T3 (es) Concentrado de fibrinogeno obtenido de plasma sanguineo, procedimiento e instalacion para su preparacion.
HN1997000146A (es) Derivados de pirimidina biciclica condensada
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
PT690675E (pt) Acido nucleico que codifica um percursor de antigenio de rejeicao de tumor
ES2164060T3 (es) Concentrado de enzima purificada y metodo de preparacion.
HN1998000020A (es) Derivados de acido arilsulfonilhidroxamico.
ATE227567T1 (de) Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
DE69516128D1 (de) Mercaptoacetylamid-1,3,4,5-tetrahydrobenzo(c)azepin-3-ein disulfidderivate als enkephalinase und ace inhibitoren
BR9502522A (pt) Composiçao concentrada em suspensao
FR2599752B1 (fr) Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
SE9300595D0 (sv) Mellanprodukter foer framstaellning av antihyperkolesterolemiska medel
DE69724062D1 (de) Benzothiophenderivate, Zwischenprodukte, Verfahren, Zubereitungen und Methoden
DK0536197T3 (da) Ren, krystallinsk form af rifapentine
PT1075480E (pt) Purificacao de carboxaldeido
IL133782A0 (en) Novel stereoselective processes for the preparation of gabapentin analogues
IL120371A (en) Process for the preparation of unsymmetrical 4,6-bis (aryloxy) pyrimidine compounds and novel intermediates thereof
BR9810481A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas.
ES2160329T3 (es) Procedimiento para la preparacion de silicatos de aluminio dispersables.
ES2148891T3 (es) Procedimiento para la fabricacion de 2-metil-2,4-diaminopentano.
PT837677E (pt) Derivados hexa-hidroxibifenilo bromados
HRP970399B1 (en) Intermediates for the preparation of 2-imidazoline-5-ones
FR2708603B1 (fr) Procédé de préparation d'hydroperoxyde de cumène.
BR9909697A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas
KR970701687A (ko) 레조르시놀로부터의 4, 6-디니트로레조르시놀의 일단계 제조방법 (One-step preparation of 4,6-dinitroresorcinol from resorcinol)
DE50115830D1 (de) Lagerungselement zur spannungsfreien Befestigung von Platten an Tragkonstruktionen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 771324

Country of ref document: ES